Investor Presentaiton

Executive summary Advanced Health Intelligence (ASX-NASDAQ:AHI) Is a global digital health solution Corporate overview AHI sells its dHaaS (digital health-as-a-service) technology to healthcare, insurance and government customer segments around the world in a business- to-business model (B-to-B). AHI completed two acquisitions in 2022, expanding its capabilities to offer mass population health monitoring using only a user's smartphone. AHI holds patents in Australia, USA, Japan, Korea, Singapore, New Zealand, China and Canada and expects to add to the patent portfolio. AHI screens for health risk stratification using only a smartphone by capturing biometric data, including vital signs, body composition, dimension, and indicative blood markers. In addition, AHI offers DermaScan which covers 588 skin conditions across 133 categories. AHI enables its partners to estimate 41 biometrics across 5 health categories in order to triage their users into directionalized care. Issuer Exchange Shares on issue As at 19 Jan 2024 NASDAQ ADR ADR Ratio 28:1, As at 19th Jan 2024 Employee headcount Current partners addressable audience Intellectual property X ASX Nasdaq Advanced Health Intelligence Ltd. Australian Securities Exchange (ASX), Nasdaq Capital Market (NASDAQ) 241,428,086 including ADR cover 1,940,773 34 across Australia, Singapore, USA, Canada, South Africa, Netherlands > 250 million addressable users across AHI's current partners 24 patents, across Australia, USA, Japan, Korea, Singapore, New Zealand, China And Canada Investor Presentation - January 2024 4

View entire presentation